Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1B, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced Solid Tumors Expressing HER2

NCT04460456 is registered in ClinicalTrials.gov with Silverback Therapeutics as lead sponsor.

NCT NCT04460456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04460456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1B, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced Solid Tumors Expressing HER2
Lead sponsor
Silverback Therapeutics
Phase
Phase 1
Overall status
Unknown status
Start date
July 27, 2020
Completion date
December 31, 2022
Enrollment
58 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive solid tumors